Directory / featured listing
$300-3,500/mo
Standard, featured, or top-of-category placement in a vetted clinic/provider directory.
Marketplace revenue, separate from CIN Core
Sponsored visibility for partners who fit the patient journey.
Casanova can monetize attention, referral placement, and partner visibility today without blending that story into CIN Core's future de-identified clinical data licensing narrative.
Discuss sponsor placementIndicative rate card
Fast revenue lines that do not require IRB approval.
Verified Partner badge
$2,500-5,000/yr
Annual quality-control badge with audit checklist, renewal review, and clear non-clinical positioning.
Sponsored content
$1,500-4,000
Case study or editorial feature with photography/video coordination through the Experience Asia network.
Qualified referral fee
$150-500 lead
Paid on confirmed consult or accepted referral; institutional enrollments can carry a larger fee.
Patient communication slot
$1,000-2,500/mo
Careful sponsor placement inside onboarding or patient communication, not clinical advice.
Recruitment placement
$200-800 screened
Later-stage CRO/trial sponsor placement only after real enrolled patient volume exists.
Who pays
Partner categories to approach first.
Bangkok longevity clinicsHealthi Life, VitalLife, StemCells21, Revival Clinic, and regenerative medicine groups that want qualified international patient flow.
Vietnam and Malaysia clinicsFV Hospital, Vinmec, and expansion-market partners once the clinical partner list is finalized.
Longevity product brandsNAD+, peptide, exosome, supplement, and protocol brands suited to sponsored content only after clinical review.
Expat and international insurersPacific Cross, Cigna Global, IMG, and Allianz Care as co-marketing or referral partners.
Long-stay and lifestyle brandsRetirement-visa, real estate, and expat services aligned with the long-stay funnel.
Compliance posture
Keep sponsor visibility separate from clinical judgment.
Directory placement and sponsored content can turn on quickly. Product sponsorship should wait for a visible clinical review process, and CRO/trial sponsor placement should wait until real enrollment and outcomes data exist. This keeps Casanova's marketplace revenue separate from CIN Core's neutral data-infrastructure story.